Antares Pharma (AIS)
Antares Pharma Profit Margin: -1.08%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
AIS Profit Margin Rankings
| Overall | 24th percentile | 3301 of 4391 |
| Sector | 46th percentile | 250 of 469 in Healthcare |
| Industry | 43rd percentile | 38 of 67 in Medical Instruments & Supplies |
AIS Profit Margin Range, Past 5 Years
| Minimum | -313.9% | Mar 2008 |
| Maximum | -1.08% | Mar 2012 |
| Average | -113.1% |
About Profit Margin
Profit margin represents the percentage of revenue that a company keeps as profit after accounting for fixed and variable costs. It is calculated by dividing net income by revenue. The profit margin is mainly used for internal comparisons, because acceptable profit margins vary between industries. In general, narrow profit margins indicate increased volatility. For companies with significant fixed costs, wide profit margins reduce the risk that a decline in sales will cause a net profit loss.
Displayed as a percentage, profit margin can be thought as the amount of profit that a company keeps per dollar of revenue. For example, if a company has a profit margin of 43%, the company keeps $.43 of each dollar of revenue.
Learn More
You may also be interested in these AIS related companies
AIS News
@ANDISIK try to get timing/Entry better next time $AIS.Over history its proven 2 bounce back,so buy big dips not tops,n you'll luv this name
about 2 hours ago by HighGrowthFinancial
about 2 hours ago by HighGrowthFinancial
@HighGrowthFinancial $AIS is not hard but impossible to predict the price movement. Kills me that I could be making $ elsewhere.
about 3 days ago by ANDISIK
about 3 days ago by ANDISIK
$AIS not buying this dip just yet, its been bouncing back from sub $3 everytime, not sure about this one though
about 3 days ago by HighGrowthFinancial
about 3 days ago by HighGrowthFinancial
@GPrime, $AIS, Example of making money elsewhere, bought SPPI yesterday at $10.76, its now at $11.20, a 4% gain.
about 3 days ago by ANDISIK
about 3 days ago by ANDISIK
$AIS, really does test your patience. If it can't hold ~ $2.90, I'm going to start getting out. Buy back when lower or go make $ elsewhere.
about 3 days ago by ANDISIK
about 3 days ago by ANDISIK
RT @casualtrader: Long $AIS Long will run into next earning date $CLSN Celsion buy @ 1,6 ~ 1,8 run up come by end of this year 8$ come
about 4 days ago by BioInvestor
about 4 days ago by BioInvestor
@casualtrader, $AIS. You should check out $SPPI, great company. I actually got back in today. ·
about 4 days ago by ANDISIK
about 4 days ago by ANDISIK
@markf @ANDISIK any other biotech ideas? Long $AIS, looking to initiate long position $ZLCS. Thoughts?
about 4 days ago by casualtrader
about 4 days ago by casualtrader
@markf $AIS not that I'm aware of.Just a safer long term biotech investment with huge potential. Don't need to put all $ in riskier biotechs
about 4 days ago by ANDISIK
about 4 days ago by ANDISIK
On 5/19/12 Columbine Capital Services upgraded $AIS from Neutral to Favorable.
about 6 days ago by ANDISIK
about 6 days ago by ANDISIK
RT @markf: $AIS on Aug 8th..?? on earnings day for $AIS next earning is Aug 7 or 8 2012 positive earning come 100%
about 10 days ago by BioInvestor
about 10 days ago by BioInvestor
Antares Pharma Appoints LeRoux Jooste Senior Vice President Pharmaceutical Sales and Marketing
May 15, 7:00AM Business Wire
May 15, 7:00AM Business Wire
Antares Pharma to Present at the 15th Annual Bank of America Merrill Lynch Health Care Conference
May 10, 7:00AM Business Wire
May 10, 7:00AM Business Wire
Antares Pharma Reports First Quarter 2012 Financial and Operating Results
May 08, 7:00AM Business Wire
May 08, 7:00AM Business Wire
Antares Pharma Announces Epinephrine Auto-Injector Settlement Agreement Between Teva and Pfizer
Apr 26, 9:26AM Business Wire
Apr 26, 9:26AM Business Wire
Watson and Antares Announce the Introduction of Gelnique 3%™, for the Treatment of Overactive Bladder
Apr 26, 7:00AM PR Newswire
Apr 26, 7:00AM PR Newswire
Antares Pharma to Present at the 11th Annual Needham Healthcare Conference
Mar 28, 7:00AM Business Wire
Mar 28, 7:00AM Business Wire
Antares Pharma and Boston Scientific Look to Make Headway in Surging Medical Supplies Industry
Mar 22, 8:20AM Marketwire
Mar 22, 8:20AM Marketwire
Antares Pharma Reports Fourth Quarter and Full Year 2011 Financial and Operating Results
Mar 12, 7:00AM Business Wire
Mar 12, 7:00AM Business Wire
Antares Pharma Appoints John J. Howarth Vice President of Corporate Affairs
Feb 27, 9:30AM Business Wire
Feb 27, 9:30AM Business Wire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AIS | 2.89 | +0.02 | +0.70% | 299.69M |
| AIRT | 9.250 | +0.17 | +1.87% | 22.66M |
| AIRM | 91.97 | -0.12 | -0.13% | 1.159B |
| AIR | 12.48 | -0.29 | -2.27% | 502.69M |
| AIQ | 1.05 | -0.02 | -1.87% | 55.99M |
| AMS | 3.09 | +0.03 | +0.98% | 14.24M |
| AMRS | 2.57 | +0.20 | +8.44% | 144.59M |
| AMRI | 2.71 | -0.05 | -1.81% | 83.39M |
| AMRC | 11.07 | -0.15 | -1.34% | 289.15M |
| AMPL | 0.185 | +0.01 | +2.83% | 10.38M |